Highlights

  • The Vision-MR Diagnostic Catheter received US FDA 510(k) clearance in January 2026.
  • NorthStar entered the US commercial market in April, with pediatric clearances announced in July.
  • A new Imricor Cardiovascular business was launched in August for MR-guided catheterisation.
  • A 1.5T interventional MRI lab configuration was introduced with an imaging technology partner in August.
  • A San Diego children’s hospital became Imricor’s first commercial US hospital customer in September.

Imricor Medical Systems, Inc. (ASX:IMR) develops magnetic resonance (MR)-compatible devices and systems for cardiac interventions performed under MRI guidance. Its technology is intended to let clinicians see soft tissue and catheter position during procedures without X-ray fluoroscopy. During 2026, the company reported US regulatory clearances, product commercialisation steps and hospital adoption initiatives, alongside work to broaden the clinical use of its interventional MR platform.

US Regulatory Milestones for Diagnostic Technology

In January 2026, Imricor Medical Systems (ASX:IMR) reported that the US Food and Drug Administration granted 510(k) clearance for its Vision-MR Diagnostic Catheter. The device is designed for use under real-time MRI guidance and represents one component of the company’s electrophysiology system. The clearance permitted US marketing of this diagnostic catheter; it did not constitute blanket approval for every Imricor product or cardiac ablation indication.

Imricor (ASX:IMR) announced the US commercial launch of its NorthStar Mapping System on 23 April 2026. NorthStar is designed to combine mapping and guidance with MR imaging during minimally invasive cardiac procedures. In July, the company reported additional FDA clearances covering pediatric use of NorthStar and the Vision-MR Diagnostic Catheter, extending the cleared population to children and young adults.

From Device Clearances to Hospital Deployment

The next step was the launch of Imricor Cardiovascular in August 2026. This business initiative focuses on radiation-free cardiac catheterisation within interventional MR laboratories, distinct from the company’s electrophysiology and ablation activities. Imricor Medical Systems (ASX:IMR) described a single-session approach that brings imaging and catheterisation into an MR-based workflow. These operational claims describe the intended service model, not universal outcomes across hospitals.

On 22 September 2026, Imricor (ASX:IMR) identified Rady Children’s Hospital-San Diego as its first commercial US hospital customer. The hospital’s planned interventional MR cardiac catheterisation programme signalled a transition from regulatory clearance towards clinical deployment. The announcement did not establish that the technology had reached widespread US adoption.

Integrated MRI Systems and Geographic Scope

An August announcement also introduced an integrated interventional MR lab configuration combining a 1.5T MRI platform with Imricor’s systems and compatible devices. Imricor Medical Systems (ASX:IMR) identified NorthStar, the Advantage-MR EP Recorder/Stimulator and Vision-MR catheter products among its technology components. Commercial availability differs across jurisdictions and device configurations, depending on applicable clearance and approvals.

This distinction matters because MRI guidance spans several related but separate functions: diagnostic catheter positioning, cardiac mapping and therapeutic ablation. The company’s own regulatory information describes European approvals for certain ablation products while US approvals for specific ablation uses remain subject to clinical and regulatory processes. Consequently, clearance of one component cannot be interpreted as approval of the entire procedure portfolio.

Execution and Regulatory Considerations

Imricor (ASX:IMR) operates in a medical device market where hospital installation, staff training, compatible infrastructure and procedural workflows affect commercial deployment. Different approvals, hospital procurement processes and the integration of multiple devices can influence the pace of adoption. Its development activities also require continued expenditure, while published commercial milestones do not independently establish future sales volumes or financial returns.

Key Insights

Imricor Medical Systems (ASX:IMR) entered several new stages of US activity in 2026: diagnostic device clearance, NorthStar commercial availability, pediatric indications and the first announced commercial US hospital customer. Its business remains centred on providing equipment for MRI-guided cardiac interventions. Regulatory boundaries and real-world deployment are essential to distinguishing an approved diagnostic capability from broader therapeutic applications.